21 Nov 2019 07:00
21 November 2019
Diurnal Group plc
("Diurnal" or the "Company")
AGM Statement
At today's Annual General Meeting of Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, the Board will make the following statement:
Diurnal's primary focus remains on progressing Chronocort® and Alkindi®, our two lead products, which are potentially valuable treatment options with a combined opportunity of over $3bn for diseases resulting from cortisol deficiency in the US and Europe.
Diurnal remains on track to submit two key regulatory filings during Q4 2019, namely a Marketing Authorisation Application submission for Chronocort® in Europe and a New Drug Application submission for Alkindi® in the US. This follows the two regulatory filings already made for Alkindi® during 2019 by our partners Medison and Emerge in Israel and Australia, respectively.
Recent pricing work has reinforced the significant commercial potential for Alkindi® and Chronocort® in the US; Diurnal's discussions with US partners around its late-stage cortisol deficiency pipeline continue to advance and it expects to conclude a licensing deal during H1 2020. Diurnal is also progressing licensing discussions in other territories and expects to announce further progress in due course.
The commercial roll out of Alkindi® in Europe continues to progress, with sales for the year to date in line with expectations.
Diurnal also continues to progress its early-stage pipeline, with positive headline results from the Company's DITEST™ (native oral testosterone formulation) Phase I proof-of-concept clinical trial, announced yesterday.
For further information, please visit www.diurnal.co.uk or contact: | |
|
|
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer |
|
Richard Bungay, Chief Financial Officer |
|
|
|
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) | +44 (0)20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl |
|
Corporate Broking: James Stearns |
|
|
|
Cantor Fitzgerald Europe (Joint Broker) | +44 (0)20 7894 7000 |
Corporate Finance: Phil Davies, Will Goode, Michael Boot |
|
Healthcare Equity Sales: Andrew Keith |
|
|
|
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway |
|
Victoria Foster Mitchell |
|
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
Date of Preparation: November 2019 Code: CORP-GB-0043